

What We Claim Is:

1. A method for the treatment of a cardiovascular-related condition, the method comprising administering to a subject susceptible to or afflicted with such condition a first amount of an aldosterone receptor antagonist and a second amount of an anti-diabetic agent, wherein the first amount of the aldosterone receptor antagonist and the second amount of the anti-diabetic agent together comprise a therapeutically-effective amount of the aldosterone receptor antagonist and anti-diabetic agent.
2. The method of Claim 1 wherein the aldosterone receptor antagonist is eplerenone.
3. The method of Claim 2 wherein the eplerenone is administered in a daily dose range from about 1 mg to about 250 mg.
4. The method of Claim 2 wherein the cardiovascular-related condition is selected from the group consisting of coronary artery disease, hypertension, cardiovascular disease, renal dysfunction, diabetic nephropathy, heart failure, cerebrovascular disease, vascular disease, retinopathy, neuropathy, hyperglycemia, hyperinsulinemia, insulin resistance, edema, endothelial dysfunction, and baroreceptor dysfunction.
5. The method of Claim 4 wherein the cardiovascular-related condition is hypertension.
6. The method of Claim 4 wherein the cardiovascular-related condition is diabetic nephropathy.
7. The method of Claim 4 wherein the cardiovascular-related condition is heart failure.

8. The method of Claim 2 wherein the anti-diabetic agent is selected from the group consisting of alpha-glucosidase inhibitors, biguanides, insulins, meglitinides, sulfonylureas, thiazolidinediones, and pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

9. The method of Claim 2 wherein the anti-diabetic agent is selected from the group consisting of miglitol, acarbose, metformin, insulin, nateglinide, repaglinide, tolbutamide, chlorpropamide, tolazamide, acetohexamide, glimepiride, glyburide, glipizide, gliclazide, pioglitazone, rosiglitazone, and pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

10. The method of Claim 2 wherein the anti-diabetic agent is miglitol.

11. The method of Claim 2 wherein the anti-diabetic agent is glipizide.

12. The method of Claim 2 wherein the anti-diabetic agent is glyburide.

13. The method of Claim 2 wherein the anti-diabetic agent is metformin.

14. The method of Claim 1 wherein the aldosterone receptor antagonist is spironolactone.

15. The method of Claim 14 wherein the cardiovascular-related condition is selected from the group consisting of coronary artery disease, hypertension, cardiovascular disease, renal dysfunction, diabetic nephropathy, heart failure, cerebrovascular disease, vascular disease, retinopathy, neuropathy, hyperglycemia, hyperinsulinemia, insulin resistance, edema, endothelial dysfunction, and baroreceptor dysfunction.

16. The method of Claim 14 wherein the anti-diabetic agent is selected from the group consisting of alpha-glucosidase inhibitors, biguanides, insulins, meglitinides, sulfonylureas, thiazolidinediones, and pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

17. The method of Claim 14 wherein the anti-diabetic agent is selected from the group consisting of miglitol, acarbose, metformin, insulin, nateglinide, repaglinide, tolbutamide, chlorpropamide, tolazamide, acetohexamide, glimepiride, glyburide, glipizide, gliclazide, pioglitazone, rosiglitazone, and pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

18. The method of Claim 14 wherein the anti-diabetic agent is miglitol.

19. The method of Claim 14 wherein the anti-diabetic agent is glipizide.

20. The method of Claim 14 wherein the anti-diabetic agent is glyburide.

21. The method of Claim 14 wherein the anti-diabetic agent is metformin.

22. The method of Claim 1 wherein the aldosterone receptor antagonist and the anti-diabetic agent are administered in a sequential manner.

23. The method of Claim 1 wherein the aldosterone receptor antagonist and the anti-diabetic agent are administered in a substantially simultaneous manner.

24. A pharmaceutical composition comprising a first amount of an aldosterone receptor antagonist, a second amount of an anti-diabetic agent, and a pharmaceutically acceptable carrier.

25. The composition of Claim 24 wherein the aldosterone receptor antagonist is eplerenone.

26. The composition of Claim 25 wherein the eplerenone is administered in a daily dose range from about 1 mg to about 250 mg.

27. The composition of Claim 25 wherein the cardiovascular-related condition is selected from the group consisting of coronary artery disease, hypertension, cardiovascular disease, renal dysfunction, diabetic nephropathy, heart failure, cerebrovascular disease, vascular disease, retinopathy, neuropathy, hyperglycemia, hyperinsulinemia, insulin resistance, edema, endothelial dysfunction, and baroreceptor dysfunction.

28. The method of Claim 27 wherein the cardiovascular-related condition is hypertension.

29. The method of Claim 27 wherein the cardiovascular-related condition is diabetic nephropathy.

30. The method of Claim 27 wherein the cardiovascular-related condition is heart failure.

31. The composition of Claim 25 wherein the anti-diabetic agent is selected from the group consisting of alpha-glucosidase inhibitors, biguanides, insulins, meglitinides, sulfonylureas, thiazolidinediones, and pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

32. The composition of Claim 25 wherein the anti-diabetic agent is selected from the group consisting of miglitol, acarbose, metformin, insulin, nateglinide, repaglinide, tolbutamide, chlorpropamide, tolazamide, acetohexamide, glimepiride, glyburide, glipizide, gliclazide, pioglitazone, rosiglitazone, and pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

33. The composition of Claim 25 wherein the anti-diabetic agent is miglitol.

34. The composition of Claim 25 wherein the anti-diabetic agent is glipizide.

35. The composition of Claim 25 wherein the anti-diabetic agent is glyburide.

36. The composition of Claim 25 wherein the anti-diabetic agent is metformin.

37. The composition of Claim 24 wherein the aldosterone receptor antagonist is spironolactone.

38. The composition of Claim 37 wherein the cardiovascular-related condition is selected from the group consisting of coronary artery disease, hypertension, cardiovascular disease, renal dysfunction, diabetic nephropathy, heart failure, cerebrovascular disease, vascular disease, retinopathy, neuropathy, hyperglycemia, hyperinsulinemia, insulin resistance, edema, endothelial dysfunction, and baroreceptor dysfunction.

39. The composition of Claim 37 wherein the anti-diabetic agent is selected from the group consisting of alpha-glucosidase inhibitors, biguanides, insulins, meglitinides, sulfonylureas, thiazolidinediones, and pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

40. The composition of Claim 37 wherein the anti-diabetic agent is selected from the group consisting of miglitol, acarbose, metformin, insulin, nateglinide, repaglinide, tolbutamide, chlorpropamide, tolazamide, acetohexamide, glimepiride, glyburide, glipizide, gliclazide, pioglitazone, rosiglitazone, and pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

41. The composition of Claim 37 wherein the anti-diabetic agent is miglitol.

42. The composition of Claim 37 wherein the anti-diabetic agent is glipizide.

43. The composition of Claim 37 wherein the anti-diabetic agent is glyburide.

44. The composition of Claim 37 wherein the anti-diabetic agent is metformin.

45. A kit containing a first amount of an aldosterone receptor antagonist and a second amount of an anti-diabetic agent.

46. The kit of Claim 45 wherein the aldosterone receptor antagonist is eplerenone.

47. The kit of Claim 46 wherein the anti-diabetic agent is selected from the group consisting of alpha-glucosidase inhibitors, biguanides, insulins, meglitinides, sulfonylureas, thiazolidinediones, and pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

48. The kit of Claim 46 wherein the anti-diabetic agent is selected from the group consisting of miglitol, acarbose, metformin, insulin, nateglinide, repaglinide, tolbutamide, chlorpropamide, tolazamide, acetohexamide, glimepiride, glyburide, glipizide, gliclazide, pioglitazone, rosiglitazone, and pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

49. The kit of Claim 45 wherein the aldosterone receptor antagonist is spironolactone.

50. The kit of Claim 49 wherein the anti-diabetic agent is selected from the group consisting of alpha-glucosidase inhibitors, biguanides, insulins, meglitinides, sulfonylureas, thiazolidinediones, and pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

51. The kit of Claim 49 wherein the anti-diabetic agent is selected from the group consisting of miglitol, acarbose, metformin, insulin, nateglinide, repaglinide, tolbutamide, chlorpropamide, tolazamide, acetohexamide, glimepiride, glyburide, glipizide, gliclazide, pioglitazone, rosiglitazone, and pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.